TB CAB

Advocates call on Otsuka to reduce the price of delamanid

Advocates ask Otsuka to lower the price of delamanid in line with Médecins sans Frontières target regimen cost of $500.

Read More →

Webinar on implementing an injectable-free regimen for drug-resistant TB - materials now available online

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB), the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) and TB Proof hosted a webinar on 16 August 2018 on implementing an injectable-free regimen for drug-resistant TB.

Read More →

The TB CAB and TAG welcome WHO recommendation of injectable-free regimens for the treatment of RR/MDR-TB

The WHO, Ministries of Health and Finance, donors, implementers, technical assistance providers, civil society, and communities must work together to ensure rapid implementation.

Read More →

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.

Read More →

Global TB CAB responds to new bedaquiline price

The TB CAB reiterates its request for Johnson & Johnson to commit to a global price for bedaquiline that is no higher than US$32 per month.

Read More →

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and DR-TB STAT will host a webinar on 1 August 2018 at 10 am New York / 4pm South Africa / 5pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB.

Read More →

Activists call on Johnson & Johnson to drop the price of bedaquiline

Activists ask the company to drop the price of bedaquiline in all markets to $32 a month or lower.

Read More →

South Africa makes bedaquiline part of its standard recommended treatment regimen for rifampicin-resistant TB

Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB; Other countries and the World Health Organization must now follow.

Read More →

Advocates call for urgent reforms of WHO TB diagnosis and treatment guidelines

Advocates call on WHO leadership to ensure rapid development of clear, consolidated guidelines for the diagnosis and treatment of TB.

Read More →

Advocates call on WHO to consolidate and revise its guidance regarding the treatment for MDR-TB

TB CAB issues a position statement on the use of bedaquiline as part of the preferred regimen for MDR-TB.

Read More →

Page 1 of 5 · Total posts: 10

1 2 Last→